Floatz logo

Tilt-123

Platinum-Resistant Fallopian Tube Carcinoma

TILT Biotherapeutics Ltd.gene_therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

72 Active assets in the Platinum-Resistant Fallopian Tube Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Women's Hospital School Of Medicine Zhejiang University
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 3BB
Cyclophosphamide
Mayo Clinic
Phase 2BB
Pembrolizumab
Roswell Park Cancer Institute
Phase 2BB
TAMOXIFEN
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3BB

View all 50 →

Same molecule, other indications

Tilt-123 is also rated in:

ovarian carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
ovarian cancerDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →